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Uncoupling Protein 3: Its Possible Biological Role and Mode
of Regulation in Rodents and Humans
Patrick Muzzin,1,3 Olivier Boss,2 and Jean-Paul Giacobino1
The recently discovered uncoupling protein 3 (UCP3) is highly homologous to the mitochondrial
inner membrane protein UCP1, which generates heat by uncoupling the respiratory chain
from oxidative phosphorylation. The thermogenic function of UCP1 protects against cold and
regulates the energy balance in rodents. We review in vitro studies investigating the uncoupling
activity of UCP3 and in vivo studies, which address UCP3 gene expression in brown adipose
tissue and skeletal muscle under various metabolic conditions. The data presented are, for the
most, consistent with an uncoupling role for UCP3 in regulatory thermogenesis. We also
discuss mediators of UCP3 regulation and propose a potential role for intracellular fatty acids
in the mechanism of UCP3 modulation. Finally, we hypothesize a role for UCP3 in the
metabolic adaptation of the mitochondria to the degradation of fatty acids.
KEY WORDS: Uncoupling proteins; fatty acids; skeletal muscle; brown adipose tissue; obesity; thermo-
genesis; gene expression.
DISCOVERY OF UNCOUPLING PROTEIN 3 ham et al., 1985; Lean et al., 1986). It was, therefore,
generally admitted that, because of the lack of BAT, there(UCP3)
was, at least under normal conditions, practically no UCP
in human adults.The first uncoupling protein (called now uncou-
pling protein 1: UCP1) was discovered by Ricquier In 1997, i.e., 21 years after the first report on
UCP1, two novel uncoupling proteins, UCP2 andand Kader (1976). It was found to be an inner mito-
chondrial membrane protein which, by dissipating the UCP3 were discovered (Fleury et al., 1997; Boss et
al., 1997). These proteins were found to belong to themitochondrial proton gradient driven by the respiratory
chain, uncouples oxidation from phosphorylation and, mitochondrial carrier protein family. In this family,
they had the highest amino acid sequence identity totherefore, produces heat instead of ATP. UCP1 was
found to be exclusively expressed in brown adipose tis- UCP1, i.e., 55 and 56%, respectively (Fleury et al.,
1997; Boss et al., 1997). The most closely relatedsued (BAT). In rodents, BAT plays an important role in
the exposure to a cold environment (non-shivering cold- mitochondrial carrier protein, 2-oxoglutarate/malate
carrier had only 32% amino acid sequence identityinduced thermogenesis) and to excess food intake (faculta-
tive diet-induced thermogenesis) (for review see Cannon with UCP2 and UCP3. The novel uncoupling proteins
were highly expressed, not only in rodents, but alsoand Nedergaard, 1985). In humans, BAT is present only
in the newborn and involutes rapidly later in life (Cunning- in humans: UCP2 in most tissues studied (Fleury et
al., 1997) and UCP3 mainly in skeletal muscle in
humans and in BAT and skeletal muscle in rodents
1 Department of Medical Biochemistry, University of Geneva, 1211 (Boss et al., 1997). Soon after the first description of
Geneva 4, Switzerland. UCP2 and UCP3, similar tissue distribution for these2 Division of Endocrinology, Beth Israel Deaconess Medical Center, two proteins were reported (Gimeno et al., 1997; Vidal-Harvard Medical School, Boston, Massachusetts 02215.
Puig et al., 1997; Gong et al., 1997). These discoveries3 Author to whom all correspondence should be sent. E-mail:
patrick.muzzin@medecine.unige.ch. reboosted the interest in UCPs as thermogenic proteins
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in humans and raised hopes for new targets in anti- One interesting observation further supports the
notion that UCP3 has an uncoupling activity. Lanniobesity therapy.
et al. (1999), in collaboration with our group, using
hypohyroid, euthyroid, and triiodothyronine (T3)-
treated rats, observed, in the skeletal muscle, a positiveIS UCP3 AN UNCOUPLING PROTEIN?
correlation between UCP3 content and mitochondria
state-4 respiration, as well as membrane proton con-In vitro Studies
ductance. The model of Lanni et al. (1999) supports
the study on transfected cells and allows to go oneThe function of UCP1 as an uncoupler of oxida-
tive phosphorylation and the specific inhibition of its step further toward the demonstration of an uncoupling
activity of UCP3 (Table I).activity by GDP are well documented (Cannon and
Nedergaard, 1985). The sequence homologies between
UCP3 and UCP1 suggested, but did not prove, that
these two proteins had similar uncoupling activities. In vivo Studies
The UCP3 function was studied by Gong et al.
(1997), who showed a decrease in the mitochondrial Short and Long Isoforms of UCP3
membrane potential in yeast transformed with UCP3,
as compared to yeast transformed with an empty vec- In our report of the cloning of human UCP3,
we described two different UCP3 clones: UCP3 longtor. These results were confirmed later, using the same
technique, by Liu et al. (1998). We used C2C12 (UCP3L) and short (UCP3S), respectively. UCP3S lacks
the VIth potential transmembrane domain and a largemyoblasts, which do not express UCP3 (Shimokawa
et al., 1998) and could also demonstrate, in a model part of the putative purine nucleotide binding domain
of UCP3 (Boss et al., 1997). The two isoforms mightcloser to isolated muscle cells, that the expression
of UCP3 significantly decreased cell mitochondrial be splice variants of the same gene as proposed by
Solanes et al. (1997). The UCP3S protein can be postu-membrane potential (Boss et al., 1998) (Table I).
It is still possible that the observed decreases in lated to be either inactive, because of the absence
of the VIth transmembrane domain or constitutivelymitochondrial membrane potential induced by UCP3
(Gong et al., 1997; Boss et al., 1998; Liu et al., 1998) active, due to the lack of inhibition by GDP, if the
latter has any inhibitory effect on UCP3 activity. Aare artefacts produced by the insertion of the
transfected protein into mitochondria. To really dem- few studies have addressed the problem of the possible
biological function of UCP3S in humans. We (O. Bossonstrate that UCP3 is an uncoupling protein, it would
be necessary to determine oxygen consumption and et al., 1997) and others (Millet et al., 1998) have
found that the two UCP3S and UCP3L transcripts arerespiratory control in a well-characterized system (per-
meabilized cells or mitochondria) and the effect on expressed at the same level in the muscle. It was also
found that muscle UCP3S and UCP3L are coordinatelythese parameters of a well-known inhibitor of UCP1
activity like GDP. One should mention that, up to now, regulated by fasting (Millet et al., 1998) and NIDDM
(Bao et al., 1998). A new insight on a possible specificthere is no evidence of an inhibitory effect of GDP on
UCP3 activity. A complementary approach would be function of UCP3S, as compared to UCP3L, was sug-
gested by a recent genetic study by Argyropoulos etthe study of oxidative phosphorylation in muscle mito-
chondria of UCP3 knockout animals as compared to al. (1998). Subjects heterozygous for an exon 6 splice
junction polymorphism, which should preclude thewild type.
Table I. Is UCP3 an Uncoupling Protein?
System Observed change References
Transformed yeast Mitochondrial membrane potential ' Gong et al., 1997;
Liu et al., 1998
Transfected C2C12 myoblasts Mitochondrial membrane potential ' Boss et al., 1998
Isolated muscle mitochondria (hyper- vs. hypothyroid state) State-4 respiration ; Lanni et al., 1999
Membrane proton conductance ;
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synthesis of UCP3L allowing only that of UCP3S, had sure. Boyer et al. (1998) have shown a strong increase
in muscle UCP3 in ground squirrels during hiberna-markedly reduced fat oxidation and a higher respira-
tory quotient, suggesting that a change in the UCP3L/ tion. In muscle, food restriction, consisting of 40%
reduction in food intake for 1 week, decreased UCP3UCP3S ratio may have an effect on lipid metabolism.
mRNA expression by 81% and more than 90% in
mouse tibialis anterior or rat red quadriceps femoris,
respectively (Boss et al., 1998a; Cusin et al., 1998).Adaptation to Metabolic Changes
Therefore, in skeletal muscle, UCP3 behaves in
response to acute cold exposure, hibernation, and foodAlthough the study of the responses of UCP3
expression to metabolic changes should allow interpre- restriction as a true thermogenic protein.
The surprise came from the effects of fasting. Atations as to whether or not this protein behaves as a
thermogenic protein, modulation data are only circum- fasting period of 48 h, indeed, increased UCP3 mRNA
expression in rat soleus and tibialis anterior, 2.2 andstantial and cannot be used to prove or disprove the
hypothesis that UCP3 is an uncoupling protein. They 6-fold, respectively (Boss et al., 1998a). Similar results
were obtained by other groups in rodents (Gong et al.,are nevertheless very illuminating for understanding
of the biological activity of the novel UCPs. 1997; Weigle et al., 1998). In humans, the same type
of observation was reported. Indeed, in lean and obesePractically, all the changes in UCP3 expression
levels reported up to now refer to UCP3 messenger. subjects maintained on a hypocaloric diet (1045 kJ/d)
a large increase in vastus lateralis muscle UCP3 mRNANo quantification of the protein has been yet reported,
because of the lack of a specific anti-UCP3 antibody. expression was observed (Millet et al., 1997, 1998).
The reason for the increase in muscle UCP3 expressionAssuming that UCP3, like UCP1, binds GDP, one
might use, as an alternative way to quantify UCP3 upon fasting is difficult to explain. It has been hypothe-
sized that during fasting, BAT activity being blunted,protein [3H]GDP binding assays, but no data on such
measurement has been reported up to now. muscle UCP3 activity increases to prevent a dangerous
drop in body temperature (Boss et al., 1998a).The activity of a thermogenic protein functionally
similar to BAT UCP1 should vary in parallel with
whole body thermogenic needs. It should be increased
upon cold exposure and during cold adaptation and MECHANISM OF UCP3 MODULATION:
POSSIBLE ROLE OF INTRACELLULARdecreased upon food restriction and fasting (Cannon
and Nedergaard, 1985). FATTY ACIDS
What is, in fact, observed in BAT? A 48-h cold
exposure increased UCP3 mRNA expression in this Weigle et al. (1998) could show that an elevation
in circulating FFA by Intralipid infusion in fed ratstissue 1.5-fold (Boss et al., 1998a). This effect was
less pronounced than that on UCP1 (about fivefold). mimicked the effect of fasting on muscle UCP3 mRNA
expression. In humans, we found a correlation in aTherefore, in rat BAT UCP3, which is expressed under
basal conditions at about the same level as UCP1 (Boss group of obese patients between circulating FFA levels
and UCP3 expression in the vastus lateralis (Boss etet al., 1997), should contribute, but less than UCP1,
to the response to cold. A fasting period of 48 h, on al., 1998b).
In BAT, cold exposure and fasting are known to,the other hand, decreased UCP3 mRNA expression in
BAT by 74% (Boss et al., 1998a). Therefore, in BAT, respectively, increase and decrease the sympathetic
nervous system activity and therefore, should increaseUCP3 behaves in response to cold and fasting as a
thermogenic protein. and decrease lipolysis and intracellular fatty acid level,
respectively (Cannon and Nedergaard, 1985). In thisWhat about skeletal muscle? A 48-h cold expo-
sure did not change UCP3 mRNA expression in rat tissue, all the above described modulations of UCP3
mRNA expression could, in theory, be explained onlytibialis anterior. Similar results were obtained by Lar-
kin et al. (1997). However, a time course study, per- by changes in intracellular fatty acids (Table II).
In muscles, which avidly take up fatty acids, theformed by Lin et al. (1998), showed that muscle UCP3
mRNA is increased between 6 and 24 h of cold expo- level of intracellular fatty acids should vary in parallel
with that of circulating FFA. It is tempting to speculatesure and is decreased after 6 days of cold acclimation.
UCP3 might, therefore, contribute to non-shivering that the increase in UCP3 expression induced by fast-
ing is the consequence of the increase in circulatingthermogenesis only in the acute response to cold expo-
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Table II. Intracellular Fatty Acids and UCP3 mRNA Expression in BAT
Theoretical changes in Observed changes in
Conditions intracellular fatty acids UCP3 expression References
Cold exposure Increase Increase Boss et al., 1998a
b3-Adrenoceptor agonista Increase Increase Savontaus et al., 1998; Yoshitomi et al., 1998
Leptin Increase Increase Cusin et al., 1998; Liu et al, 1998; Scarpace et al., 1998
Fasting Decrease Decrease Boss et al., 1998a
Streptozotocin diabetes Decrease Decrease Kageyama et al., 1998
a No effect or a decrease in UCP3 mRNA expression observed by Gong et al., 1997 and Emilsson et al., 1998, respectively.
FFA level, excluding known endocrine adaptations to STZ diabetic animals, FFA acts as a signal for shifting
the control of body temperature from BAT UCP1 tostarvation (Samec et al., 1998a, b). This hypothesis is
supported by results of Samec et al. (1998b), who muscle UCP3 activity.
PPARg, which was shown to bind directly mono-showed that, in 46-h fasted rats, the administration of
a dose of nicotinic acid, which completely prevented and polyunsaturated fatty acids (Kliewer et al., 1997),
could play a role in the effect of fatty acids on UCP3the fasting-induced increase in FFA, decreased UCP3
mRNA expression in soleus muscle (slow twitch, oxi- expression. In the only studies performed up to now
to test this hypothesis, the PPARg agonists like pioglita-dative) by 70%. This same dose of nicotinic acid did
not change UCP3 mRNA expression in the gastrocne- zone or thiazolidinedione, administered to rodents,
were found to increase UCP3 mRNA expression inmius and tibialis anterior (fast twitch glycolytic, fast
twitch oxidative glycolytic, respectively) muscles. BAT (Matsuda et al., 1998; Kelly et al., 1998) and,
not change (Matsuda et al., 1998; Kelly et al., 1998)Oxidative muscles are more dependent on circulating
lipids as food substrates than glycolytic muscles. In or decrease (Shimokawa et al., 1998b) UCP3 expres-
sion in skeletal muscle. It could also be proposed thatfact, the plasma membrane fatty acid-binding protein
(FABPpm) level was found to be higher in slow than in the stimulatory effect of fatty acids on UCP3 expres-
sion is indirect, involving b-oxidation and still uniden-fast twitch muscles and to correlate with the oxidative
capacity of the muscle fiber type (Turcotte et al., 1997). tified intermediary products of this degradation
pathway.The sensitivity of oxidative, but not glycolytic muscles,
to nicotinic acid described by Samec et al. (1998b)
support, therefore, the hypothesis that circulating FFA
are the major determinants of the induction by fasting OTHER UCP3 MODULATORS
of UCP3 expression in oxidative muscles and that, in
glycolytic muscles, another mechanism is involved in the b3-Adrenergic Agonists
control of this phenomenon. It is noteworthy that the
sympathetic nervous system, which seems to play a cen- We have found that a 30-h administration of a
b3-adrenoceptor agonist Ro16-8714 increased UCP3tral role in the control of BAT UCPs expression, is unlikely
to play a role in the control of UCP3 expression in muscle mRNA expression in obese Zucker ( fa/fa) rat BAT
(Boss, Muzzin, and Giacobino, unpublished observa-during fasting (Dulloo et al., 1988) (Table III).
An interesting hypothesis would be that, when tions). Savontaus et al. (1998), in collaboration with
our group, found that a chronic treatment with theBAT activity is blunted, like in the fasted state or in
Table III. Circulating FFA and UCP3 mRNA Expression in Muscle
Theoretical changes in Observed changes in
Conditions circulating FFA UCP3 expression References
Intralipid infusion Increase Increase Weigle et al., 1998
Fasting Increase Increase Boss et al., 1998a; Gong et al., 1997; Weigle et al., 1998;
Millet et al., 1997, 1998; Samec et al., 1998a,b
Streptozotocin diabetes Increase Increase Kageyama et al., 1998
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b3-agonist BRL 35135 also increased UCP3 mRNA totally corrected by insulin treatment. It is not quite
clear whether or not insulin exerts a direct inhibitoryexpression in obese Zucker ( fa/fa) rat BAT. Similar
results were obtained with CL 316,243 by Yoshitomi effect on muscle UCP3 expression. In STZ diabetic
rats, the effect of a lack of insulin might be indirectet al. (1998) using hyperglycemic KK mice. It can
be proposed that these effects of the b3-adrenoceptor via the increase in circulating FFA (Kageyama et
al., 1998).agonists, like those of cold exposure in BAT described
above, are mediated by an increase in intracellular On the other hand, it might be proposed that the
inhibitory effects of a chronic CL 316,243 treatmentfatty acids. One should mention that Gong et al. (1997)
did not observe any effect of an acute CL 316,243 on hyperglycemic KK mouse muscle UCP3 expression
reported by Yoshitomi et al. (1998) is, in fact, due totreatment on BAT UCP3 mRNA expression and that
Emilsson et al. (1998) observed a decrease in BAT the restoration of insulin sensitivity by this drug.
Again, this effect might be mediated by the decreaseUCP3 expression by an acute BRL 35135 treatment.
The reasons for these discrepancies are not understood, in circulating FFA induced by CL 316,243 treatment
(Yoshitomi et al., 1998).but they might have to do with the different durations
of the respective treatments. In human patients, results that could help to
understand the effects of insulin on muscle UCP3The b3-adrenoceptor is considered not to be
expressed at a significant level in skeletal muscle. expression are contradictory. In NIDDM, indeed,
Krook et al. (1998) have reported a decrease and BaoNevertheless, the administration of b3-adrenoceptor
agonists in vivo has been shown to affect UCP3 mRNA et al. (1998) an increase in vastus lateralis muscle
UCP3 expression.expression in this tissue. The effects observed con-
sisted of the induction by BRL 35135 of UCP3 mRNA Other studies are definitely needed to answer the
question of a direct effect of insulin on muscleexpression in soleus muscle in lean Zucker rats (Emils-
son et al., 1998) and in no change in obese ( fa/fa) rats UCP3 expression.
(Savontaus et al., 1998; Emilsson et al., 1998). They
might be mediated by the muscle atypical b-adreno-
ceptor reported to avidly bind BRL 35135 in this tissue Triiodothyronine (T3)
(Liu et al., 1996). This hypothesis was corroborated
by the fact that CL 316,243, which does not seem to T3 treatment or hyperthyroidism are known to
increase thermogenesis in rodents and in humans. T3be an agonist for the muscle atypical b-adrenoceptor
(Liu et al., 1996), not only did not increase, but even administration in euthryroid rodents has been repro-
ducibly shown to increase UCP3 mRNA expressiondecreased UCP3 mRNA expression in hyperglycemic
KK mouse femoral muscle (Yoshitomi et al., 1998). in BAT (Gong et al., 1997; Larkin et al., 1997) and
in skeletal muscle (Gong et al., 1997; Larkin et al.,The fact that BRL 35135 does not stimulate muscle
UCP3 expression in obese Zucker ( fa/fa), whereas it 1997; Lanni et al., 1999). These results show that
UCP3 in BAT and muscle behaves in response to T3does so in lean rats (Savontaus et al., 1998; Emilsson
et al., 1998), might indicate that obesity induces a as a thermogenic protein and might, at least in part,
be the mediator of the in vivo thermogenic response“resistance” of the muscle atypical b-adrenoceptor to
its specific agonist. to T3.
The mechanism of action of b3-adrenoceptor ago-
nists on muscle UCP3 expression is unknown. It might
be mediated by stimulation of muscle lipolysis and Leptin
consequent increase in intracellular fatty acids and/or
by the known second messenger of the b3-adrenocep- We have administered leptin intracerebroventric-
ularly in rats. Using pair-fed animals as controls, wetor, cAMP.
found that leptin increased UCP3 mRNA level twofold
in BAT and prevented the decrease in UCP3 mRNA
level induced by pair feeding in muscle (Cusin et al.,Insulin
1998). Similar data were obtained by Scarpace et al.
(1998), who showed an increase in BAT UCP3 mRNAIn STZ diabetic rats, Kageyama et al. (1998), in
collaboration with our group, observed a decrease and expression after subcutaneous leptin infusion with a
minipump, and by Liu et al. (1998), who showed anan increase in UCP3 mRNA expression in BAT and
gastrocnemius muscle, respectively. Both effects were increase in muscle UCP3 mRNA expression after
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administration of adenoviral vectors expressing leptin and, under some circumstances, in muscle may suggest
that UCP3 is a fatty acid mitochondrial carrier, butin obese (ob/ob) mice.
The effects of leptin on BAT have been shown to it should not be considered an argument against an
uncoupling activity of UCP3.be mediated by stimulation of the sympathetic nervous
system (Collins et al., 1996). It can, therefore, be pro- It might suggest, however, the interesting hypoth-
esis that, when a cell expressing UCP3 is faced withposed that these effects, like those of cold exposure
in BAT, are secondary to an increase in intracellular the necessity of burning fatty acids instead of glucose,
it shifts its mitochondrial oxidative phosphorylation tofatty acids. The effect of leptin on muscle is difficult
to explain and the elucidation of its mechanism needs a less coupled state. Fatty acid degradation would,
therefore, be associated with a greater energy dissipa-further study.
Altogether, the effects of leptin on UCP3 expres- tion than glucose degradation.
sion are in line with a general positive effect of leptin
on energy dissipation.
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